May 23, 2024

Intensity-Modulated Reirradiation Therapy With Nivolumab in Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma

Key Points

Key points are not available for this paper at this time.

Abstract

Intensity-modulated radiation therapy (IMRT) reirradiation of nonmetastatic recurrent or second primary head and neck squamous cell carcinoma (HNSCC) results in poor progression-free survival (PFS) and overall survival (OS).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Saba et al. (Thu,) studied this question.

www.synapsesocial.com/papers/68e68ab9b6db643587612bd9 — DOI: https://doi.org/10.1001/jamaoncol.2024.1143

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape· 2012 · 2,137 citations
Methodological standards for using the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in cancer clinical trials· 2022 · 10 citations
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck· 2016 · 5,032 citations
Salvage Re-Irradiation for Recurrent Head and Neck Cancer

Authors

Nabil F. Saba

Stuart J. Wong

Tahseen H. Nasti

Journals

JAMA Oncology

Actions

Institutions

Emory University

Cleveland Clinic

Medical College of Wisconsin

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Intensity-Modulated Reirradiation Therapy With Nivolumab in Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion